Sonoma Pharmaceuticals (SNOA) Capital Expenditures Growth (3y) (2013 - 2026)
Sonoma Pharmaceuticals (SNOA) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 75.58% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 28.56% |
| 10 | Sonoma Pharmaceuticals | 179.80 | -2.40 Mn | 2.18 Mn | -46.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.56% |
| Dec 31, 2025 | 14.88% |
| Sep 30, 2025 | -26.32% |
| Jun 30, 2025 | 66.42% |
| Mar 31, 2025 | -8.82% |
| Dec 31, 2024 | 25.99% |
| Sep 30, 2024 | 1.32% |
| Jun 30, 2024 | -53.27% |
| Mar 31, 2024 | -77.58% |
| Dec 31, 2023 | -76.49% |
| Sep 30, 2023 | -64.58% |
| Jun 30, 2023 | -31.11% |
| Mar 31, 2023 | -31.46% |
| Dec 31, 2022 | 30.89% |
| Sep 30, 2022 | 27.92% |
| Jun 30, 2022 | 24.22% |
| Mar 31, 2022 | 64.22% |
| Dec 31, 2021 | -67.45% |
| Sep 30, 2021 | -5.90% |
| Jun 30, 2021 | 21.98% |